What is the evidence for high-dose statins in secondary prevention of CVD events?
The meta-analysis by de Vries et al. (2014) compared the incidence of major CV and cerebrovascular events between standard-dose statins and placebo (n=4,351) and standard-dose statins with intensive- dose statins (n=4,805) for secondary prevention in patients with DM. There was a statistically significant reduction in major CV and cerebrovascular events in favor of the more intensive statin dose group versus standard dose (RR: 0.91, 95% CI: 0.84 0.98).